News-LTZ Therapeutics

Press Releases

LTZ Named 2026 "Immunology Innovation of the Year" by BioTech Breakthrough

Recognition Shines a Spotlight on LTZ's Proprietary Myeloid Engager Platform

LTZ Doses First Participant in Phase 1/1b Trial of LTZ-232 for mCRC and Other Solid Tumors

LTZ Therapeutics Names Phillip Lee as Chief Financial Officer

LTZ Therapeutics Announces FDA Clearance of IND Application for LTZ-232 to Treat Advanced Metastatic Colorectal Cancer and Other Solid Tumors

LTZ Therapeutics Raises $38 Million in Support of Advancing Myeloid Engager Immunotherapy Pipeline

GSK and LTZ announce strategic collaboration to advance novel myeloid cell engagers in oncology

LTZ Therapeutics Announces Strategic Collaboration with Eli Lilly to Advance Development of its Myeloid Engager Platform for Autoimmune Diseases

LTZ Therapeutics Announces FDA Clearance of IND Application to Initiate Trial of First-in-Class Myeloid Engager Immunotherapy, LTZ-301

LTZ Therapeutics Announces Over $20 Million Series A Financing for Development of its Myeloid Engager-Based Immunotherapy Pipeline

LTZ Announces over $10 Million Pre-A+ Financing to Advance Development of its Immunotherapy Pipeline to Treat Cancer and Autoimmune Diseases

LTZ Therapeutics Secures $17 Million Pre-Series A Financing for Immunotherapy Development to Treat Cancer & Other Complex Diseases

In The News

Follow Us

Stay ln Touch

General Inquiries
info@ltztherapeutics.com
Business Development
vivian.tian@ltztherapeutics.com
Locations

Redwood City, USA
1100 Island Dr., Suite 103, Redwood City, CA, 94065
Shenzhen, China
Room 3004, Building B, New Building of Research Institute of Tsinghua University in Shenzhen, Yuehai Sub-district, High-tech Zone Community, Gaoxin South 39th Road, Nanshan District, Shenzhen 518057

@ 2026 LTZ Therapeutics Inc., All Rights Reserved.

Privacy Policy | Term of Use | Contact Us

为了更好的呈现效果，移动端请竖屏浏览